BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11867193)

  • 1. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?
    Buti M; Cotrina M; Valdes A; Jardi R; Rodriguez-Frias F; Esteban R
    J Hepatol; 2002 Mar; 36(3):445-6. PubMed ID: 11867193
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B virus resistance to antivirals: clinical implications and management.
    Zoulim F
    J Hepatol; 2003; 39 Suppl 1():S133-8. PubMed ID: 14708691
    [No Abstract]   [Full Text] [Related]  

  • 3. [Lamivudine resistance impedes hepatitis B therapy].
    Eggers HJ
    Fortschr Med; 1997 Apr; 115(12):5. PubMed ID: 9235306
    [No Abstract]   [Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Van Bömmel F; Schernick A; Hopf U; Berg T
    Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
    [No Abstract]   [Full Text] [Related]  

  • 5. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns.
    Honkoop P; Niesters HG; de Man RA; Osterhaus AD; Schalm SW
    J Hepatol; 1997 Jun; 26(6):1393-5. PubMed ID: 9210628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine for chemotherapy-induced reactivation of HBV: prophylaxis or treatment?
    Mancuso A; Pagliaro L
    Am J Gastroenterol; 2002 May; 97(5):1268-9. PubMed ID: 12014746
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatitis B viral genotypes and lamivudine resistance.
    Kao JH; Liu CJ; Chen DS
    J Hepatol; 2002 Feb; 36(2):303-4. PubMed ID: 11830346
    [No Abstract]   [Full Text] [Related]  

  • 8. Lamivudine resistant occult HBV: implications for public health?
    Bowden S; Bartholomeusz A; Locarnini S
    J Hepatol; 2003 Apr; 38(4):526-8. PubMed ID: 12663248
    [No Abstract]   [Full Text] [Related]  

  • 9. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics.
    Mutimer D
    J Hepatol; 2005 Aug; 43(2):200-2. PubMed ID: 15975684
    [No Abstract]   [Full Text] [Related]  

  • 10. Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B.
    Cainelli F; Longhi MS; Concia E; Vento S
    Am J Gastroenterol; 2001 May; 96(5):1651-2. PubMed ID: 11374725
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistence of YMDD variants after withdrawal of Lamivudine.
    van der Eijk AA; Niesters HG; Pas SD; de Man RA
    J Hepatol; 2002 Feb; 36(2):304-5. PubMed ID: 11830347
    [No Abstract]   [Full Text] [Related]  

  • 12. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains.
    Kuwahara R; Kumashiro R; Inoue H; Tanabe R; Tanaka E; Hino T; Ide T; Koga Y; Sata M
    Dig Dis Sci; 2004 Feb; 49(2):300-3. PubMed ID: 15104374
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count).
    Haverkamp M; Smit M; Weersink A; Boucher CA; Hoepelman AI
    AIDS; 2003 Jul; 17(10):1572-4. PubMed ID: 12824802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
    Laubscher B; Gehri M; Roulet M; Wirth S; Gerner P
    J Pediatr Gastroenterol Nutr; 2005 Apr; 40(4):518-20. PubMed ID: 15795605
    [No Abstract]   [Full Text] [Related]  

  • 15. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-resistant viral hepatitis.
    Wright M; Main J; Thomas HC
    J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
    [No Abstract]   [Full Text] [Related]  

  • 17. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients.
    Fontaine H; Thiers V; Chrétien Y; Zylberberg H; Poupon RE; Bréchot C; Legendre C; Kreis H; Pol S
    Transplantation; 2000 May; 69(10):2090-4. PubMed ID: 10852602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation.
    Panos GZ; Lampropoulos KM; Angelousi AG; Charatsis GG; Falagas ME
    J Clin Gastroenterol; 2007 Feb; 41(2):222-3. PubMed ID: 17245225
    [No Abstract]   [Full Text] [Related]  

  • 20. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.
    van Bömmel F; Wünsche T; Schürmann D; Berg T
    Hepatology; 2002 Aug; 36(2):507-8. PubMed ID: 12143063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.